University of Pittsburgh Seal Link to Homepage
Archive Service Center Link University Library System Link

Autoimmunity Appendix

# Article Information # of Cites
1Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE: FK 506 - A new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 128:781-785, 1992.
2Oddis CV, Sciurba FC, Abu-Elmagd K, Starzl TE: Tacrolimus in the treatment of refractory polymyositis with interstitial lung disease. Lancet 353:1762-1763, 1999.
3McCauley J, Bronsther O, Fung J, Starzl TE: Successful treatment of cyclosporine induced hemolytic uremic syndrome with FK 506. Lancet 2:1516, 1989.
4Abu-Elmagd K, Jegasothy BV, Ackerman CD, Thomson AW, Rilo H, Nikolaidis N, Van Thiel D, Fung JJ, Todo S, Starzl TE: Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc 23:3328-3329, 1991.
5Randhawa PS, Markin RS, Starzl TE, Demetris AJ: Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Am J Surg Pathol 14:538-547, 1990.
6Starzl TE: History of Clinical Transplantation. World J Surg 24:759-782, 2000. (Also published verbatim in: Starzl TE: A History of Clinical Transplantation. In: Surgery: Basic Science and Clinical Evidence. (eds. JA Norton, R Bollinger, AE Chang, SJ Mulvihill, S Lowry, H Pass, R Thompson). Springer Verlag, New York, NY. 2001 and 2008, 1st and 2nd editions).
7Abu-Elmagd K, Van Thiel D, Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Thomson AW, Starzl TE: FK 506: A new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 23:3322-3324, 1991.
8Abu-Elmagd K, Van Thiel DH, Jegasothy BV, Jacobs JC, Carroll P, Rilo R, Ackerman C, Fung J, Starzl TE: Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK506). An Intern Med 119:595-598, 1993.
9McCauley J, Tzakis AG, Fung JJ, Todo S, Starzl TE: Treatment with FK 506 of steroid resistent focal sclerosing glomerulonephritis (FSGN) of childhood. Lancet 335:674, 1990.
10Murase N, Lieberman I, Nalesnik M, Mintz D, Todo S, Drash AL, Starzl TE: The effect of FK 506 on spontaneous diabetes in the BB rat. Diabetes 39:1584-1586, 1990.
11Thomson AW, Nalesnik M, Abu-Elmagd K, Starzl TE: Influence of FK 506 on T lymphocytes, Langerhans cells and the expression of cytokine receptors and adhesions molecules in psoriatic skin lesions: A preliminary study. Transplant Proc 23:3330-3331, 1991.
12McCauley J, Shapiro R, Scantlebury V, Gilboa N, Jordan M, Jensen C, Naik A, Tzakis A, Ellis D, Starzl TE: FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. Transplant Proc 23:3354-3356, 1991.
13Groth CG, Brent LB, Calne RY, Dausset JB, Good RA, Murray JE, Shumway NE, Schwartz RS, Starzl TE, Terasaki PI, Thomas ED, van Rood JJ: Historical landmarks in clinical transplantation: conclusions from the concensus conference at the University of California, Los Angeles (UCLA). World J Surg 24:834-843, 2000.
14Carroll PB, Tzakis AG, Ricordi C, Rilo HR, Abu-Elmagd K, Murase N, Zeng Y-J, Alejandro R, Mintz D, Starzl TE: The use of FK 506 in new-onset type I diabetes in man. Transplant Proc 23:3351-3353, 1991.
15Delaney CP, Murase N, Chen-Woan M, Fung JJ, Starzl TE, Demetris AJ: Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat: a relationship between allo- and autoimmunity. J Clin Invest 97:217-225, 1996.
16Murase N, Lieberman I, Nalesnik M, Mintz D, Todo S, Starzl TE: Prevention of spontaneous diabetes in the BB rat with FK 506. Lancet 336:373-374, 1990.
17Lemster B, Huang LL, Irish W, Woo J, Carroll PB, Abu-Elmagd K, Rilo HR, Johnson N, Russell-Hall R, Fung JJ, Starzl TE, Eidelman B, Thomson AW: Influence of FK506 (Tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity 19:89-98, 1994.
18Nikolaidis NL, Abu-Elmagd K, Thomson AW, Rilo HR, Irish WD, Van Thiel DH, Fung JJ, Starzl TE: Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. Transplant Proc 23:3325-3327, 1991.
19McMichael J, Lieberman R, Doyle H, McCauley J, Van Thiel D, Thomson A, Fung J, Starzl TE: Computer-guided concentration-controlled trials in autoimmune disorders. In: Therapeutic Drug Monitoring Raven Press, Ltd, New York, 1993, 15:510-513
20Carrieri G, Murase N, Woo, J, Nalesnik M, Azzarone A, Funakoshi Y, Thomson AW, Todo S, Starzl TE: Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. Transplant Proc 23:3357-3359, 1991.
21Carroll PB, Rilo HL, Abu-Elmagd K, Johnson N, Carter C, Wright H, Jegasothy B, Starzl TE, Van Thiel DH: Effect of tacrolimus (FK506) in dystrophic epidermolysis bullosa: rationale and preliminary results (letter). Arch Dermatol 130(11):1457-1458, 1994.
22MacSween RNM, Ono K, Bell PRF, Thomason CM, Starzl TE: Experimental allergic throiditis in rats: suppression by heterologous (rabbit) anti-lymphocyte sera to lymph node, thymic and splenic lymphocytes. Clin Exp Immunol 6:273-278, 1970.